Group 1 - The Rosen Law Firm is reminding purchasers of Cytokinetics, Inc. common stock from December 27, 2023, to May 6, 2025, about the lead plaintiff deadline on November 17, 2025 [1] - Investors who purchased Cytokinetics common stock during the specified period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and interested parties can join by contacting the Rosen Law Firm [3][6] Group 2 - The lawsuit alleges that Cytokinetics made false and misleading statements regarding the timeline for the New Drug Application (NDA) submission and approval process for aficamten, specifically regarding expected FDA approval in the second half of 2025 [5] - The company failed to disclose material risks related to the submission of a Risk Evaluation and Mitigation Strategy (REMS), which could delay the regulatory process [5]

Core Viewpoint - Rosen Law Firm is reminding purchasers of Fortinet, Inc. common stock about the upcoming lead plaintiff deadline for a class action lawsuit related to misleading statements made by the company regarding its business performance and product upgrades [1][2]. Group 1: Class Action Details - The class action lawsuit pertains to Fortinet common stock purchases made between November 8, 2024, and August 6, 2025, with a lead plaintiff deadline set for November 21, 2025 [1][2]. - Investors who purchased Fortinet stock during the specified period may be eligible for compensation without incurring out-of-pocket fees through a contingency fee arrangement [1]. Group 2: Allegations Against Fortinet - The lawsuit alleges that Fortinet made materially false and misleading statements about a "record" round of FortiGate unit upgrades, claiming it would generate between $400 million to $450 million in product revenue for 2025 and 2026 [4]. - It is claimed that the company misrepresented the sustainability and impact of the refresh cycle, which was said to consist of old products that represented a "small percentage" of the company's business [5]. - The lawsuit contends that Fortinet concealed the true number of FortiGate firewalls eligible for upgrades and misled investors about the momentum of the refresh cycle, which was pushed through rapidly in a short timeframe [5].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Snap Inc. securities between April 29, 2025, and August 5, 2025, of the upcoming lead plaintiff deadline on October 20, 2025, for a class action lawsuit [1]. Group 1: Class Action Details - Investors who bought Snap securities during the specified Class Period may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by contacting Rosen Law Firm [3][6]. - To serve as lead plaintiff, individuals must file a motion with the Court by October 20, 2025 [3]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting their own success in this area [4]. - The firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time, and has consistently ranked highly in terms of settlements since 2013 [4]. - In 2019, the firm secured over $438 million for investors, showcasing their capability in recovering funds for clients [4]. Group 3: Case Allegations - The lawsuit alleges that Snap's management misled investors by presenting overly optimistic projections regarding advertising revenue and growth, while downplaying existing execution issues [5]. - It is claimed that when the true situation was revealed, investors suffered damages due to the discrepancies between reported expectations and actual performance [5].

Core Viewpoint - Rosen Law Firm has filed a class action lawsuit on behalf of investors who purchased securities of Spirit Aviation Holdings, Inc. during the specified class period, highlighting potential financial misrepresentations by the company [1][5]. Group 1: Lawsuit Details - The class action lawsuit is aimed at purchasers of Spirit Aviation securities between May 28, 2025, and August 29, 2025 [1]. - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A lead plaintiff must move the Court by December 1, 2025, to represent other class members in the litigation [3]. Group 2: Allegations Against Spirit Aviation - The complaint alleges that Spirit Aviation was at significant risk of failing to meet its debt obligations and may have to file for Chapter 11 bankruptcy protection within months [5]. - It is claimed that the defendants overstated the company's financial condition and liquidity while downplaying adverse market conditions [5]. - The lawsuit asserts that the public statements made by the defendants were materially false and misleading, leading to investor damages when the true situation was revealed [5]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company at the time [4]. - The firm was ranked No. 1 by ISS Securities Class Action Services for the number of settlements in 2017 and has consistently ranked in the top 4 since 2013 [4]. - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering funds for clients [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of Tronox Holdings plc during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1][3]. Group 1: Class Action Details - Investors who bought Tronox common stock between February 12, 2025, and July 30, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by November 3, 2025 [3][5]. - The lawsuit alleges that Tronox's management made misleading statements about the company's growth and performance in its pigment and zircon commercial division, which ultimately led to a decline in sales and increased costs [5]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting its own success in recovering hundreds of millions for investors [4]. - The firm has been recognized for its leadership in securities class action settlements, achieving the largest settlement against a Chinese company at the time and ranking highly in settlement numbers since 2013 [4].

Core Points - Rosen Law Firm is reminding purchasers of KBR, Inc. securities from May 6, 2025, to June 19, 2025, about the November 18, 2025, lead plaintiff deadline in a securities class action lawsuit [1][5] - Investors who purchased KBR securities during the specified period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - The lawsuit alleges that KBR made materially false and misleading statements regarding its partnership with HomeSafe and the ability to fulfill the Global Household Goods Contract, leading to investor damages when the truth was revealed [5] Next Steps - Interested parties can join the KBR class action by visiting the provided link or contacting the law firm directly for more information [3][6] - A class has not yet been certified, and investors can choose to remain absent or select their own counsel [7] Rosen Law Firm's Credentials - The firm has a strong track record in securities class actions, having achieved significant settlements, including the largest against a Chinese company at the time [4] - Rosen Law Firm has been consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions for investors [4]

Details of the case: According to the lawsuit, defendants made false and/or misleading statements and/or failed to disclose that: (1) the MOLBREEVI (a clinical trial for the treatment of a rare lung disease) Biologics License Application ("BLA") lacked sufficient information regarding MOLBREEVI's chemistry, manufacturing, and/or controls; (2) accordingly, the FDA was unlikely to approve the MOLBREEVI BLA in its current form; (3) the foregoing made it unlikely that Savara would complete submission of the MO ...

Core Points - Rosen Law Firm is reminding purchasers of Quantum Corporation securities about a class action lawsuit with a lead plaintiff deadline of November 3, 2025 [1][3] - Investors who purchased Quantum Corporation securities during the specified class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] Case Details - The lawsuit alleges that Quantum Corporation made false or misleading statements and failed to disclose that it improperly recognized revenue for the fiscal year ended March 31, 2025, necessitating a restatement of financial statements for the fiscal third quarter ended December 31, 2024 [5] - The lawsuit claims that these misstatements led to material inaccuracies regarding the company's business, operations, and prospects, resulting in investor damages when the truth was revealed [5] Legal Representation - Investors are encouraged to select qualified legal counsel with a successful track record in securities class actions, as many firms may not have the necessary experience or resources [4] - The Rosen Law Firm has a history of significant recoveries for investors, including over $438 million in 2019 alone, and has been recognized for its leadership in securities class action settlements [4]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Snap Inc. securities between April 29, 2025, and August 5, 2025, of the upcoming lead plaintiff deadline on October 20, 2025, for a class action lawsuit [1][3]. Group 1: Class Action Details - Investors who bought Snap securities during the specified Class Period may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must act by the lead plaintiff deadline to represent other class members [3][5]. - The lawsuit alleges that Snap's management misrepresented the company's advertising revenue and growth potential, leading to investor losses when the truth was revealed [5]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting its own success in recovering hundreds of millions for investors [4]. - The firm has been recognized for its leadership in securities class action settlements, achieving the largest settlement against a Chinese company at the time and ranking highly in settlement numbers since 2013 [4].

Core Viewpoint - Rosen Law Firm is reminding purchasers of Cytokinetics, Inc. common stock of the upcoming lead plaintiff deadline for a class action lawsuit related to misleading statements about the company's New Drug Application process for aficamten [1][5]. Group 1: Class Action Details - The class period for the lawsuit is from December 27, 2023, to May 6, 2025, and the lead plaintiff deadline is November 17, 2025 [1]. - Investors who purchased Cytokinetics common stock during the class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by contacting the Rosen Law Firm [3][6]. Group 2: Legal Representation - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4]. - The firm has achieved significant settlements in the past, including the largest securities class action settlement against a Chinese company at the time and has consistently ranked highly in securities class action settlements [4]. Group 3: Case Specifics - The lawsuit alleges that Cytokinetics made false and misleading statements regarding the timeline for the NDA submission and approval process for aficamten, specifically regarding expected FDA approval in the second half of 2025 [5]. - The company failed to disclose material risks related to the submission of a Risk Evaluation and Mitigation Strategy, which could delay the regulatory process, leading to investor damages when the true details were revealed [5].